Major Depressive Disorder
📧 Sign up to get email alerts when something new happens for Major Depressive Disorder.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2025-01-29FDA Approved: OLANZAPINE AND FLUOXETINE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for Teva Pharmaceuticals' generic olanzapine and fluoxetine combination product.
-
FDA approval · 2025-01-29FDA Approved: SERTRALINE HYDROCHLORIDE — Supplemental Application (Lupin Pharmaceuticals, Inc.)
FDA approved Lupin Pharmaceuticals' supplemental application for sertraline hydrochloride (generic sertraline), authorizing the generic prod…
-
FDA approval · 2025-01-29FDA Approved: BUPROPION HYDROCHLORIDE SR — Supplemental Application (Solco Healthcare US LLC)
FDA approved a supplemental application for Bupropion Hydrochloride sustained-release from Solco Healthcare US LLC, indicating approval of a…
-
FDA approval · 2025-01-29FDA Approved: BUPROPION HYDROCHLORIDE — Supplemental Application (Alembic Pharmaceuticals Limited)
FDA approved a supplemental application for Bupropion hydrochloride by Alembic Pharmaceuticals Limited under the ANDA pathway, authorizing t…
-
FDA approval · 2025-01-29FDA Approved: BUPROPION HYDROCHLORIDE — Supplemental Application (Amneal Pharmaceuticals of New York LLC)
FDA approved a supplemental application for a generic form of bupropion hydrochloride from Amneal Pharmaceuticals of New York LLC.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2025-01-24FDA Approved: ARIPIPRAZOLE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for ARIPIPRAZOLE from Aurobindo Pharma Limited.
-
FDA approval · 2025-01-24FDA Approved: ARIPIPRAZOLE — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approved Amneal Pharmaceuticals' supplemental application for aripiprazole (ARIPIPRAZOLE) under the ANDA pathway.
-
FDA approval · 2025-01-24FDA Approved: ARIPIPRAZOLE — Supplemental Application (Alembic Pharmaceuticals Inc.)
The FDA approved a supplemental application for aripiprazole from Alembic Pharmaceuticals, enabling the marketing of a generic version. This…
-
FDA approval · 2025-01-24FDA Approved: ARIPIPRAZOLE — Supplemental Application (Advagen Pharma Ltd)
The FDA approved Advagen Pharma Ltd's supplemental application for aripiprazole, authorizing a generic ARIPIPRAZOLE product with the same in…
-
FDA approval · 2025-01-24FDA Approved: ARIPIPRAZOLE — Supplemental Application (Apotex Corp.)
FDA approves a supplemental application from Apotex Corp. for aripiprazole (ANDA204094), authorizing changes to the generic product's approv…
-
FDA approval · 2025-01-24FDA Approved: ARIPIPRAZOLE — Supplemental Application (Camber Pharmaceuticals, Inc.)
FDA approved a supplemental application for aripiprazole oral from Camber Pharmaceuticals, resulting in approval of this generic product's l…
-
FDA approval · 2025-01-24FDA Approved: ARIPIPRAZOLE — Supplemental Application (VistaPharm, LLC)
FDA approved a supplemental application for aripiprazole from VistaPharm, LLC, for a generic aripiprazole product.
-
FDA approval · 2025-01-23FDA Approved: ARIPIPRAZOLE — Supplemental Application (Lannett Company, Inc.)
FDA approved a supplemental application for Lannett's generic aripiprazole, authorizing a generic formulation of the antipsychotic.
-
FDA approval · 2025-01-23FDA Approved: ARIPIPRAZOLE — Supplemental Application (Dr. Reddy's Laboratories Inc)
FDA approved a supplemental application to authorize a new orally disintegrating tablet formulation of aripiprazole from Dr. Reddy's Laborat…
-
FDA approval · 2025-01-23FDA Approved: ARIPIPRAZOLE — Supplemental Application (Advagen Pharma Ltd)
FDA approved Advagen Pharma Ltd's supplemental application for aripiprazole (ARIPIPRAZOLE) under ANDA216351.
-
FDA approval · 2025-01-17FDA Approved: SPRAVATO — Supplemental Application (Janssen Pharmaceuticals Inc.)
FDA approved a supplemental application for SPRAVATO (esketamine hydrochloride) from Janssen Pharmaceuticals Inc.
-
FDA approval · 2025-01-15FDA Approved: DESVENLAFAXINE SUCCINATE — Original Application (Macleods Pharmaceuticals Limited)
FDA approves the original ANDA for desvenlafaxine succinate (generic) from Macleods Pharmaceuticals Limited.
-
FDA approval · 2025-01-14FDA Approved: VILAZODONE HYDROCHLORIDE — Supplemental Application (Teva Pharmaceuticals, Inc.)
FDA approved Teva's supplemental application for vilazodone hydrochloride, updating the drug's labeling under its existing approval.
-
FDA approval · 2025-01-14FDA Approved: VILAZODONE HYDROCHLORIDE — Supplemental Application (Northstar Rx LLC)
FDA approved Northstar Rx LLC's supplemental application for vilazodone hydrochloride (generic vilazodone).
-
FDA approval · 2025-01-14FDA Approved: ESCITALOPRAM OXALATE — Supplemental Application (Rising Pharma Holdings, Inc.)
FDA approved a supplemental application for escitalopram oxalate from Rising Pharma Holdings, Inc., confirming regulatory approval for the g…
-
FDA approval · 2025-01-13FDA Approved: ARIPIPRAZOLE — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA supplemental approval for ARIPIPRAZOLE by Amneal Pharmaceuticals LLC under an ANDA (ANDA 203906). This document records the supplemental…
-
FDA approval · 2025-01-13FDA Approved: ARIPIPRAZOLE — Supplemental Application (VistaPharm, LLC)
FDA approved a supplemental application for aripiprazole by VistaPharm, LLC (ANDA 212870). The authorization pertains to changes to the appr…
-
CLINICAL_TRIALS approval · 2025-01-10Clinical Trial Update: Duloxetine Compassionate Use in Patients Who Have Completed a Previous Neuroscience Duloxetine Clinical Trial
Clinical trial update indicates that duloxetine, sponsored by Eli Lilly, has been approved for marketing in relation to a compassionate-use …
-
FDA approval · 2025-01-03FDA Approved: VILAZODONE HYDROCHLORIDE — Supplemental Application (Accord Healthcare Inc.)
FDA approved Accord Healthcare's supplemental application for vilazodone hydrochloride, a generic version of the antidepressant, indicating …
-
FDA approval · 2025-01-03FDA Approved: VILAZODONE HYDROCHLORIDE — Supplemental Application (Exelan Pharmaceuticals Inc.)
The FDA approved a supplemental application for vilazodone hydrochloride submitted by Exelan Pharmaceuticals Inc.